N Onetto

1.2k total citations
21 papers, 948 citations indexed

About

N Onetto is a scholar working on Oncology, Dermatology and Hematology. According to data from OpenAlex, N Onetto has authored 21 papers receiving a total of 948 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 5 papers in Dermatology and 4 papers in Hematology. Recurrent topics in N Onetto's work include Cancer Treatment and Pharmacology (8 papers), Chemotherapy-related skin toxicity (5 papers) and Acute Myeloid Leukemia Research (4 papers). N Onetto is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), Chemotherapy-related skin toxicity (5 papers) and Acute Myeloid Leukemia Research (4 papers). N Onetto collaborates with scholars based in United States, Canada and Malaysia. N Onetto's co-authors include Renzo Canetta, Michaele C. Christian, Michael Friedman, D. Vena, Michael Hawkins, Edward L. Trimble, Jason S. Fisherman, John Nemunaitis, Beth Levy and Carlos Rodríguez and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

N Onetto

21 papers receiving 908 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
N Onetto United States 14 651 181 141 139 130 21 948
Robert D. Legare United States 14 449 0.7× 75 0.4× 90 0.6× 230 1.7× 150 1.2× 35 822
B. Lathan Germany 14 646 1.0× 145 0.8× 115 0.8× 47 0.3× 206 1.6× 35 1.3k
F Carnino Italy 17 439 0.7× 80 0.4× 398 2.8× 140 1.0× 70 0.5× 39 914
Mona Ridderheim Sweden 13 307 0.5× 31 0.2× 391 2.8× 109 0.8× 197 1.5× 26 825
N. Mylonakis Greece 19 745 1.1× 40 0.2× 63 0.4× 78 0.6× 294 2.3× 65 1.1k
SJ Horning United States 18 884 1.4× 349 1.9× 73 0.5× 39 0.3× 127 1.0× 39 1.7k
Arto Leminen Finland 28 538 0.8× 67 0.4× 590 4.2× 293 2.1× 415 3.2× 60 1.9k
L. Kayitalire France 17 745 1.1× 35 0.2× 158 1.1× 160 1.2× 163 1.3× 40 1.1k
Donna E. Levy United States 15 483 0.7× 232 1.3× 24 0.2× 77 0.6× 256 2.0× 24 1.5k
Elżbieta Nowara Poland 18 526 0.8× 42 0.2× 124 0.9× 220 1.6× 359 2.8× 70 1.0k

Countries citing papers authored by N Onetto

Since Specialization
Citations

This map shows the geographic impact of N Onetto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N Onetto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N Onetto more than expected).

Fields of papers citing papers by N Onetto

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N Onetto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N Onetto. The network helps show where N Onetto may publish in the future.

Co-authorship network of co-authors of N Onetto

This figure shows the co-authorship network connecting the top 25 collaborators of N Onetto. A scholar is included among the top collaborators of N Onetto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N Onetto. N Onetto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Clark, Gary M., Pablo J. Cagnoni, Mieke Ptaszynski, et al.. (2005). P-946 Why do non smokers with non-small cell lung cancer (NSCLC) who receive erlotinib have better clinical outcomes than smokers?. Lung Cancer. 49. S368–S368. 2 indexed citations
2.
Gelmon, Karen A., Hal W. Hirte, B. Fisher, et al.. (2004). A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers. Investigational New Drugs. 22(3). 263–275. 22 indexed citations
3.
Bacon, Monica, et al.. (1997). Long term survivors from a European-Canadian trial of paclitaxel in platinum-pretreated ovarian cancer (OVCA). European Journal of Cancer. 33. S119–S119. 1 indexed citations
4.
Gelmon, Karen A., Sean OʼReilly, Anthony W. Tolcher, et al.. (1996). Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer.. Journal of Clinical Oncology. 14(4). 1185–1191. 54 indexed citations
5.
Swenerton, K., Paul Hoskins, Gavin Stuart, et al.. (1996). A phase I study of bi-weekly paclitaxel/cisplatin as initial therapy for advanced ovarian cancer. Annals of Oncology. 7(10). 1077–1079. 5 indexed citations
6.
Abrams, Jeffrey S., D. Vena, Janet H. Baltz, et al.. (1995). Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial.. Journal of Clinical Oncology. 13(8). 2056–2065. 111 indexed citations
7.
Seidman, Andrew D., Russell K. Portenoy, T. J. Yao, et al.. (1995). Quality of Life in Phase II Trials: a Study of Methodology and Predictive Value in Patients With Advanced Breast Cancer Treated With Paclitaxel Plus Granulocyte Colony-Stimulating Factor. JNCI Journal of the National Cancer Institute. 87(17). 1316–1322. 85 indexed citations
8.
Marty, M., N. Tubiana-Mathieu, F. Morvan, et al.. (1995). Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancer.. PubMed. 22(4 Suppl 8). 33–9. 38 indexed citations
9.
Hg, Klingemann, et al.. (1994). Granulocyte-macrophage colony-stimulating factor after autologous marrow transplantation for Hodgkin's disease.. PubMed. 5(1-2). 1–13. 3 indexed citations
10.
Rusthoven, James J., E. Eisenhauer, J. Mazurka, et al.. (1993). Phase I Clinical Trial of Recombinant Human Interleukin-3 Combined With Carboplatin in the Treatment of Patients With Recurrent Ovarian Carcinoma. JNCI Journal of the National Cancer Institute. 85(10). 823–825. 11 indexed citations
11.
Trimble, Edward L., D. Vena, Michael Hawkins, et al.. (1993). Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.. Journal of Clinical Oncology. 11(12). 2405–2410. 207 indexed citations
12.
OʼReilly, Sean, Karen A. Gelmon, N Onetto, et al.. (1993). Phase I trial of recombinant human granulocyte-macrophage colony-stimulating factor derived from yeast in patients with breast cancer receiving cyclophosphamide, doxorubicin, and fluorouracil.. Journal of Clinical Oncology. 11(12). 2411–2416. 7 indexed citations
13.
Peereboom, David M., Ross C. Donehower, E. Eisenhauer, et al.. (1993). Successful re-treatment with taxol after major hypersensitivity reactions.. Journal of Clinical Oncology. 11(5). 885–890. 86 indexed citations
14.
Arbuck, Susan G., Renzo Canetta, N Onetto, & Michaele C. Christian. (1993). Current dosage and schedule issues in the development of paclitaxel (Taxol).. PubMed. 20(4 Suppl 3). 31–9. 44 indexed citations
15.
Onetto, N, et al.. (1993). Overview of Taxol safety.. PubMed. 131–9. 63 indexed citations
16.
17.
Nemunaitis, John, Claudio Anasetti, Rainer Storb, et al.. (1992). Phase II trial of recombinant human granulocyte-macrophage colony- stimulating factor in patients undergoing allogeneic bone marrow transplantation from unrelated donors. Blood. 79(10). 2572–2577. 37 indexed citations
18.
Nemunaitis, John, Claudio Anasetti, Rainer Storb, et al.. (1992). Phase II trial of recombinant human granulocyte-macrophage colony- stimulating factor in patients undergoing allogeneic bone marrow transplantation from unrelated donors. Blood. 79(10). 2572–2577. 45 indexed citations
19.
Hoang, T, Beth Levy, N Onetto, André Haman, & Carlos Rodríguez. (1989). Tumor necrosis factor alpha stimulates the growth of the clonogenic cells of acute myeloblastic leukemia in synergy with granulocyte/macrophage colony-stimulating factor.. The Journal of Experimental Medicine. 170(1). 15–26. 61 indexed citations
20.
Onetto, N, et al.. (1987). In vitro biochemical tests to evaluate the response to therapy of acute leukemia with cytosine arabinoside or 5-AZA-2'-deoxycytidine.. PubMed. 14(2 Suppl 1). 231–7. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robert D. Legare Breakdown of academic impact, for papers by B. Lathan Breakdown of academic impact, for papers by F Carnino Breakdown of academic impact, for papers by Mona Ridderheim Breakdown of academic impact, for papers by N. Mylonakis Breakdown of academic impact, for papers by SJ Horning Breakdown of academic impact, for papers by Arto Leminen Breakdown of academic impact, for papers by L. Kayitalire Breakdown of academic impact, for papers by Donna E. Levy Breakdown of academic impact, for papers by Elżbieta Nowara
Rankless by CCL
2026